Neuroblastoma exoDNA spanned the entirety ofthe exome, could be used to identify genetic variations conferring resistance(TP53, RAS, ALK), andcarried tumor-specific mutations including multiple known neuroblastoma tumorsuppressors and oncogenes (ALK, SHANK2,FGFR1, BRAF, etc.)(52). This evidence concerns the gene SHANK2 and neuroblastoma.